AVNR Share Price

Open 16.96 Change Price %
High 16.98 1 Day 0.00 0.00
Low 16.96 1 Week 0.00 0.00
Close 16.96 1 Month 0.00 0.00
Volume 8430307 1 Year 0.00 0.00
52 Week High 9.78
52 Week Low 5.26
AVNR Important Levels
Resistance 2 16.98
Resistance 1 16.97
Pivot 16.97
Support 1 16.95
Support 2 16.94
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
AAPL 115.59 -2.25%
AAPL 115.59 -2.25%
DELL 13.86 0.22%
SIRI 4.24 1.19%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
OGXI 0.55 48.65%
SCHS 0.12 33.33%
WRES 0.09 28.57%
LGCY 1.73 27.21%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
ESMC 0.48 23.08%
CPSL 0.13 18.18%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR)

AVNR Technical Analysis 5
As on 12th Jan 2015 AVNR Share Price closed @ 16.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.96 & Strong Buy for SHORT-TERM with Stoploss of 15.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
AVNR Target for October
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AVNR Other Details
Segment EQ
Market Capital 369051584.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.avanir.com
AVNR Address
20 Enterprise
Suite 200
Aliso Viejo, CA 92656
United States
Phone: 949-389-6700
Fax: 949-389-6701
AVNR Latest News
Interactive Technical Analysis Chart Avanir Pharmaceuticals, Inc. ( AVNR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Avanir Pharmaceuticals, Inc.
AVNR Business Profile
AVANIR Pharmaceuticals, Inc. (AVANIR), incorporated in August 1998, is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA). NUEDEXTA is the FDA-approved treatment for PBA, which occurs secondary to a range of neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes occur out of proportion or incongruent to the patient’s underlying emotional state. NUEDEXTA is a combination of two components: dextromethorphan hydrobromide, the ingredient active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and N-Methyl-D-aspartic acid (NMDA), receptors in the brain. Diabetic peripheral neuropathic pain (DPN pain), which arises from nerve injury, can result in a chronic and debilitating form of pain. AVANIR has completed a Phase III clinical trial for AVP-923 in the treatment of patients with DPN pain. AVP-923 also demonstrated improvements in a number of key secondary endpoints, including the pain relief ratings scale and the pain intensity ratings scale. In September 2009, it reported on secondary efficacy endpoints from the double-blind phase of the AVP-923 STAR trail in PBA, including an endpoint measuring reduction of pain in patients with underlying multiple sclerosis (MS).